Le Lézard
Classified in: Health, Business
Subject: VEN

Global urology leader Advanced MedTech co-leads SonoMotion's US$10 million Series B fundraising


SINGAPORE, Nov. 12, 2019 /PRNewswire/ -- Advanced MedTech Holdings (AMTH), Southeast Asia's largest medical device business, today announces it has co-led a US$10 million Series B funding in SonoMotion, a US-based medical device startup, together with its existing investors MedVenture Partners, Inc and BioVentures Investors, to support its development of non-invasive solutions for kidney stones.

The funds raised will fund a pivotal study of Break Wave(TM), SonoMotion's ultrasound solution that fragments kidney stones non-invasively. SonoMotion also plans to launch Stone Clear(TM), a non-invasive ultrasound-based tool to reposition kidney stones within the kidney and ureter, in 2020. Both technologies aim to bring greater convenience and comfort for patients and physicians, offering new alternatives in stone management that potentially remove the need for anesthesia or ionizing radiation.

Commenting on the investment, Abel Ang, Group Chief Executive of Advanced MedTech, said:

"Supporting SonoMotion's development of Break Wave(TM) and Stone Clear(TM) is in line with our commitment to investing in and advancing the most innovative, non-invasive solutions for urologists globally. Our focus is to offer the best patient experience and stone-free outcomes from the technologies we are engaged with. The SonoMotion team has impressed us with their approach to developing disruptive stone management technologies and we look forward to working closely with them to realize their strategic objectives."

Dr Oren Levy, Chief Executive Officer of SonoMotion, added:

"2020 is set to be a transformational year for SonoMotion and the new funds we have raised will enable us to reach key milestones in the development of our novel urology technology in the coming months. We are delighted to welcome Advanced MedTech as a new investor. We greatly respect the team's expertise and leadership in urology and look forward to working closely with them."

For more information, please contact:

Weikang Lee

Advanced MedTech

+65 6572 6074 

weikang.lee@advanced-medtech.com

 

Emma Thompson / Tianning He

Spurwing Communications

+65 6751 2021

[email protected]

 

About Advanced MedTech

Advanced MedTech is the largest medical device business in Southeast Asia. It is a global medical technology leader with a core focus in urology devices and services. Headquartered in Singapore, with operations in US, Germany, Spain, France, Italy, China, Malaysia and Japan, the Company serves millions of patients and physicians in 100 countries worldwide. Advanced MedTech makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world. Advanced MedTech is a wholly-owned subsidiary of Temasek. For more information on Advanced MedTech, please visit advanced-medtech.com .

About SonoMotion:

SonoMotion is a Silicon Valley based medical device start-up that is developing non-invasive solutions for the treatment of kidney stones.  

For more information on SonoMotion, please visit http://www.Sonomotion.com/

SOURCE Advanced MedTech


These press releases may also interest you

at 07:50
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...

at 07:45
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...

at 07:30
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....



News published on and distributed by: